Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Basal Cell 3Skin Neoplasms 2Neoplasms 2Platinum-Resistant Fallopian Tube Carcinoma 1Neoplasms, Basal Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Basal Cell Nevus Syndrome 1

Interventions

Magnetic Resonance Spectroscopy 6lutetium Lu 177 dotatate 4Specimen Handling 4Proton Therapy 3Bevacizumab 3gallium Ga 68 dotatate 2abemaciclib 2Protons 2Observation 2Ga(III)-DOTATOC 2Everolimus 2Elasticity Imaging Techniques 2trametinib 1regorafenib 1pembrolizumab 1olaparib 1neratinib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1capivasertib 1cabozantinib 1brigatinib 1auricularum 1apatinib 1X-Rays 1Watchful Waiting 1Thrombectomy 1Tablets 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Meningioma × HhAntag691 × Clear all
NCT02523014 2026-06-02

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
124 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡